Contact
Cindy Still – (251) 943-5015, [email protected]
Jane Denmark – [email protected] – (251) 937-4246
Save Money On Your Rx
- Propranolol reduces tremors in Parkinson's diseaseon December 23, 2024 at 6:53 pm
The standard medication levodopa does not always work against tremors in Parkinson's disease, especially in stressful situations. Propranolol, however, does work during stress, providing insight into the role of the stress system in tremors. MRI scans reveal that propranolol directly inhibits activity in the brain circuit that controls tremors. Doctors may consider this medication when levodopa is ineffective.
- 'Dancing the blues away' seen in brain imaging in people with Parkinson's disease, new study findson December 18, 2024 at 10:50 pm
Dancing lowers the depression associated with Parkinson's disease, and the benefits can be seen in multiple ways, a new study shows.
- Study identifies potential new drug for Parkinson's-related cognitive decline, dementiaon November 19, 2024 at 6:26 pm
A recently published study found that a tiny protein called PNA5 appears to have a protective effect on brain cells, which could lead to treatments for the cognitive symptoms of Parkinson's disease and related disorders.
- Researchers identify a potential biomarker of Parkinson's disease progressionon November 12, 2024 at 5:30 pm
Researchers have identified a potential biomarker of Parkinson's disease progression. According to the new study, patients with a slow progression of the pathology would have a significant increase in the levels of a molecule called ecto-GPR37 in the cerebrospinal fluid.
- Scientists discover key to preventing neurodegeneration in Parkinson's and related disorderson November 1, 2024 at 4:37 pm
A team of researchers has uncovered a groundbreaking mechanism in the formation of harmful protein aggregates that lead to neurodegenerative diseases such as Parkinson's Disease. The team, led by Professor Norifumi Shioda and Associate Professor Yasushi Yabuki, identified for the first time that unique RNA structures called G-quadruplexes (G4s) play a central role in promoting the aggregation of alpha-synuclein, a protein associated with neurodegeneration. By demonstrating that inhibiting G4 assembly could potentially prevent the onset of synucleinopathies, this discovery positions G4 as a promising target for early intervention in these diseases.